Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10877931 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL5733148 | 0.80 | — | — | |
| SCHEMBL11878568 | 0.76 | — | — | |
| SCHEMBL584119 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL875610 | 0.71 | — | — | |
| SCHEMBL6668072 | 0.69 | — | — | |
| Hydrochloric Acid SCHEMBL10702300 | 0.68 | — | — | |
| SCHEMBL6663276 | 0.67 | — | — | |
| SCHEMBL6666966 | 0.67 | — | — | |
| SCHEMBL48991 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470786-B2 | Method for manufacture of ceftriaxone sodium | LUPIN LIMITED (IN) | 2008-12-30 | — | — | US | disclosed |
| EP-1996601-A2 | PROCESS FOR THE PRODUCTION OF A CHLORINATING REAGENT AND ITS USE IN THE PREPARATION OF CHLORINATED SUGARS | V.B. MEDICARE PVT. LTD. (IN) | 2008-12-03 | — | — | EP | disclosed |
| US-7452990-B2 | 4-halo-2-oxyimino-3-oxo butyric acid-N,N-dimethyl formiminium chloride chlorosulfate; cephalosporins that may be prepared from the intermediate include cefdinir, cefditoren pivoxil, cefepime, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoselis, cefotaxime, cefpirome, cefpodoxime proxetil, etc | LUPIN LIMITED (IN) | 2008-11-18 | — | — | US | disclosed |
| WO-2007099557-A2 | PROCESS FOR THE PRODUCTION OF A CHLORINATING REAGENT AND ITS USE IN THE PREPARATION OF CHLORINATED SUGARS | V. B. MEDICARE PVT. LTD. (IN) | 2007-09-07 | — | — | WO | disclosed |
| US-20070049749-A1 | Method for Manufacture of Ceftriaxone Sodium | LUPIN LIMITED (RESEARCH PARK) (IN) | 2007-03-01 | — | — | US | disclosed |
| US-20070015917-A1 | Method For Manufacture of Ceftriaxone Sodium | LUPIN LIMITED (RESEARCH PARK) (IN) | 2007-01-18 | — | — | US | disclosed |
| US-20070004916-A1 | Process for the production of cefotaxime sodium | WOCKHARDT LIMITED | 2007-01-04 | — | — | US | disclosed |
| US-20060135761-A1 | 4-halo-2-oxyimino-3-oxo butyric acid-N,N-dimethyl formiminium chloride chlorosulfate; cephalosporins that may be prepared from the intermediate include cefdinir, cefditoren pivoxil, cefepime, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoselis, cefotaxime, cefpirome, cefpodoxime proxetil, etc | LUPIN LIMITED (IN) | 2006-06-22 | — | — | US | disclosed |
| EP-1575913-A1 | NOVEL INTERMEDIATES FOR SYNTHESIS OF CEPHALOSPORINS AND PROCESS FOR PREPARATION OF SUCH INTERMEDIATES | Lupin Limited (IN) | 2005-09-21 | — | — | EP | disclosed |
| US-20050059820-A1 | Method for manufacture of ceftriaxone sodium | LUPIN LIMITED (IN) | 2005-03-17 | — | — | US | disclosed |
| WO-2004058695-A1 | NOVEL INTERMEDIATES FOR SYNTHESIS OF CEPHALOSPORINS AND PROCESS FOR PREPARATION OF SUCH INTERMEDIATES | LUPIN LIMITED (IN) | 2004-07-15 | — | — | WO | disclosed |
| EP-0791597-B1 | Method for manufacture of cephalosporins and intermediates thereof | LUPIN LAB LTD (IN) | 2000-07-12 | — | — | EP | disclosed |
| US-5945532-A | Method for manufacture of cephalosporin and intermediates thereof | LUPIN LABORATORIES LIMITED (IN) | 1999-08-31 | — | — | US | disclosed |
| US-5856502-A | Method for manufacture of cephalosporin and intermediates thereof | LUPIN LABORATORIES LIMITED (IN) | 1999-01-05 | — | — | US | disclosed |
| US-5739346-A | Dimethyl formiminium chloride chlorosulphate derivatives useful as intermediates for producing cephalosporins | LUPIN LABORATORIES LIMITED (IN) | 1998-04-14 | — | — | US | disclosed |
| EP-0791596-A1 | Method for manufacture of cephalosporins and intermediates thereof | LUPIN LABORATORIES LIMITED (IN) | 1997-08-27 | — | — | EP | disclosed |
| EP-0791597-A1 | Method for manufacture of cephalosporins and intermediates thereof | LUPIN LABORATORIES LIMITED (IN) | 1997-08-27 | — | — | EP | disclosed |
| EP-0347777-B1 | Process for preparing cephalosporins and intermediates therefor | BIOCHEMIE SA (ES) | 1994-11-09 | — | — | EP | disclosed |
| US-5037988-A | Process for preparing cephalosporins and intermediates therefor | GEMA S.A. (ES) | 1991-08-06 | — | — | US | disclosed |
| EP-0347777-A2 | Process for preparing cephalosporins and intermediates therefor | BIOCHEMIE S.A. (ES) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049749-A1 | Method for Manufacture of Ceftriaxone Sodium | TREH, CHAT, MRPL21 | CA2 1218/4885CA1 1613/4885 |
| US-20050059820-A1 | Method for manufacture of ceftriaxone sodium | TREH, CHAT, MRPL21 | CA2 1218/4885CA1 1613/4885 |
| US-20070004916-A1 | Process for the production of cefotaxime sodium | TALDO1, CEPT1, ADH1A | CA2 1301/4885CA1 2153/4885 |
| US-20070015917-A1 | Method For Manufacture of Ceftriaxone Sodium | TREH, CHAT, MRPL21 | CA2 1218/4885CA1 1613/4885 |
| US-20060135761-A1 | 4-halo-2-oxyimino-3-oxo butyric acid-N,N-dimethyl formiminium chloride chlorosulfate; cephalosporins that may be prepared from the intermediate include cefdinir, cefditoren pivoxil, cefepime, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoselis, cefotaxime, cefpirome, cefpodoxime proxetil, etc | CYP2F1, CYP2W1, CYP4F11 | CA2 704/4885CA1 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.